Veterinary Dermatology Drugs Market Size, Share, Growth, Trends, and Global Industry Analysis: By Product Type (Antibiotics, NSAIDS, Veterinary antifungal drugs, Others), By Animal Type (Food Animal, Small Animal, Equine, Others), By End-user (Veterinary hospitals, Veterinary clinics, Others), and Region Forecast 2020-2031

Veterinary Dermatology Drugs Market size was valued at US$ 3,465.7 million in 2023 and is poised to grow at a CAGR of 6.2% from 2024-2030. The global market is projected to expand at a robust growth rate over the forecast period. The veterinary profession has experienced a dramatic shift over the past few decades. Several demographic and socioeconomic factors have contributed to drastic changes, including livestock, food production, social attitudes, urbanization, and increased adoption of companion animals are expected to fuel the market over the forecast period. Atopic dermatitis is the common cause of itching in companion animals. Atopy is a genetically determined predisposition to become allergic to airborne pollens such as weeds, grass, trees, house dust, and molds. In companion animals dogs, cats atopic dermatitis is the most common cause of chewing, biting, and rubbing as well as chronic skin and ear infections. The surge in the prevalence of chronic skin disorders is anticipated to boost the market revenue size. Increasing demand for the farm animal and poultry sector is expected to boost the market.

Rising awareness regarding various dermatological disorders and treatment methods, and favorable government initiatives in order to increase farm animal production are expected to create demand for the market in the future. Animals are susceptible to numerous chronic skin disorders. Some skin tumors can be treated using medical therapy or cryotherapy. Skin disorders can occur due to various agents such as allergens, burns, external irritants, and trauma (Viral, bacterial, fungal, other parasitic). The evolution of chronic skin diseases and increased mergers & acquisitions to offer better products are able to offer novel products to the market. Rising awareness among pet lovers and increased health checkups are expected to create lucrative opportunities in the future.

Key Developments:

• On October 11, 2023: Zoetis has officially launched 2 FDA approved drugs (bedinvetmab injection and Oclacitinib chewable tablets) for pain control associated with osteoarthritis (OA) in dogs and control of pruritus associated with allergic dermatitis and atopic dermatitis in dogs aged 1 year or older respectively.
• On Sept 19, 2024: Elanco Animal Health announced the U.S. Food and Drug Administration (FDA) has approved Zenrelia™, a safe, highly effective, and convenient once-daily oral JAK inhibitor for control of pruritus (itching) associated with allergic dermatitis and control of atopic dermatitis in dogs at least 12 months of age.
• On February 3, 2025: Zoetis Announced the U.S. Label Update for Librela® (bedinvetmab injection), a Treatment to Control Canine Osteoarthritis (OA) Pain